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Efficacy and safety of dronedarone was shown in the ATHENA trial for paroxysmal or persistent atrial fibrillation (AF) patients. Further
trials revealed safety concerns in patients with heart failure and permanent AF. This review summarizes insights from recent real-world
studies and meta-analyses, including reports on efficacy, with focus on liver safety, mortality risk in patients with paroxysmal/persistent AF,
and interactions of dronedarone with direct oral anticoagulants. Reports of rapidly progressing liver failure in dronedarone-prescribed
patients in 2011 led to regulatory cautions about potential liver toxicity. Recent real-world evidence suggests dronedarone liver safety
profile is similar to other antiarrhythmics and liver toxicity could be equally common with many Class III antiarrhythmics. Dronedarone
safety concerns (increased mortality in patients with permanent AF) were raised based on randomized controlled trials (RCT)
(ANDROMEDA and PALLAS), but comedication with digoxin may have increased the mortality rates in PALLAS, considering the
dronedarone–digoxin pharmacokinetic (PK) interaction. Real-world data on apixaban–dronedarone interactions and edoxaban RCT obser-
vations suggest no significant safety risks for these drug combinations. Median trough plasma concentrations of dabigatran 110 mg during
concomitant use with dronedarone are at acceptable levels, while PK data on the rivaroxaban–dronedarone interaction are unavailable. In
RCTs and real-world studies, dronedarone significantly reduces AF burden and cardiovascular hospitalizations, and demonstrates a low
risk for proarrhythmia in patients with paroxysmal or persistent AF. The concerns on liver safety must be balanced against the significant
reduction in hospitalizations in patients with non-permanent AF and low risk for proarrhythmias following dronedarone treatment.
...................................................................................................................................................................................................
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Introduction
Dronedarone is a non-iodinated benzofuran developed specifically
for the treatment of atrial fibrillation (AF), designed to retain the effi-
cacy of amiodarone, but with an improved safety profile.
Dronedarone was approved in the European Union (EU) for rate
and rhythm control of AF in 2009, following placebo-controlled trials
in patients with AF (EURIDIS, ADONIS, ERATO, and ATHENA), and
in comparison to amiodarone (DIONYSOS). The ATHENA trial
showed that dronedarone significantly reduced the composite
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endpoint of cardiovascular (CV) hospitalization or all-cause death in
patients with paroxysmal or persistent AF [hazard ratio (HR) 0.76, 95%
confidence interval (CI) 0.69–0.84; P< 0.001] vs. placebo (Table 1).1
The efficacy of dronedarone in maintaining sinus rhythm (SR) was
shown in the ADONIS and EURIDIS trials, with dronedarone reduc-
ing the risk of adjudicated AF recurrence by 26% (P= 0.02) and 29%
(P= 0.006) vs. placebo from day 5 to 12 months post-randomization,
respectively.3 Rhythm control is an important factor for the quality of
life (QoL) of patients with AF, therefore, it may be preferable com-
pared with rate control.10 Along with this, the prospective, open-
label IMPULS study showed that after 12 months of treatment with
dronedarone in 342 patients with paroxysmal or persistent AF, QoL
was improved vs. baseline by þ16.0± 23.5 points (P< 0.0001), as
measured by the psychological domain of the AF-QoL questionnaire.
The percentage of patients in SR increased from 44.6% at baseline to
70.2% at 12 months following dronedarone treatment.11 Similarly, in
a recent observational study of 824 Taiwanese patients with paroxys-
mal or persistent AF, dronedarone improved QoL following
6 months of treatment, as demonstrated by an increase in total score
from 67.5± 15.1 (baseline) to 74.6± 11.5 (6 months) in an AF Effect
on Quality of Life questionnaire.12 Notably, two recent randomized
controlled trials (RCT), CABANA and CAPTAF, found that catheter
ablation resulted in greater improvements in QoL of patients with
symptomatic AF compared with antiarrhythmic drug (AAD) therapy
at 12 months, with the limitation that no sham-ablation procedure
was performed in the AAD treatment arm.13,14 However, in the
CAPTAF trial, it could be demonstrated that the greater improve-
ment in QoL was directly related to a greater reduction in AF burden
in the ablation vs. AAD arm.14
While dronedarone was designed to have a better safety profile
than amiodarone, results from RCTs identified safety concerns in se-
lected patient populations. The ANDROMEDA study indicated that
dronedarone was not safe in patients with recently decompensated se-
vere heart failure (HF), and the PALLAS trial raised safety concerns in
patients with permanent AF. These studies led to the contraindication
of dronedarone in patients with permanent AF and in patients with
symptoms of HF in the EU. The potential effects of dronedarone on
liver function resulted in the European Medicines Agency (EMA) issu-
ing warnings and requiring monthly liver function tests (LFT) for the
first 6 months of treatment, followed by a reduced frequency thereaf-
ter. In addition, concerns were raised about potential drug–drug inter-
actions between dronedarone and direct oral anticoagulants (DOAC).
....................................................................................................................................................................................................................
Table 1 Clinical trials investigating the safety and efficacy of dronedarone
Endpoints Clinical trial No. of
patients
AF patient population Controls Efficacy vs. placebo
Rhythm-based DAFNE2 270 Paroxysmal/persistent Placebo 55% relative risk reduction in time to first
AF recurrence
ADONIS3 625 Paroxysmal/persistent Placebo 26% reduction in the risk of adjudicated
AF recurrence from day 5 to 12 months
post-randomization
EURIDIS3 612 Paroxysmal/persistent Placebo 29% reduction in the risk of adjudicated
AF recurrence from day 5 to 12 months
post-randomization
DIONYSOS4 504 Persistent Amiodarone 600 mg od
for 28 days, then 200 mg
od for at least 6 months
Incidence of the composite primary
endpoint was 75.1% vs. 58.8% with
amiodarone after 12 months’ treatment
HESTIA5 112 Patients with permanent
pacemakers
Placebo 54.4% reduction in AF burden
HARMONY6 134 Paroxysmal with dual-chamber
programmable pacemakers
Placebo 59% reduction in AF burden with com-
bined treatment of dronedarone (225
mg bid) and ranolazine (750 mg bid)
Rate control-
based
ERATO7 174 Permanent, resting heart rate
>80 b.p.m.
Placebo Reduction of mean ventricular rate by
11.7 b.p.m. after 14 days
Combined ANDROMEDA8 627 Systolic dysfunction, advanced
CHF NYHA Class III or IV
Placebo Prematurely discontinued due to
increased deaths (n = 25) in the
dronedarone arm compared to placebo
(n = 12)
ATHENA1 4628 Elderly patients with paroxysmal
or persistent
Placebo 0.76 HR in all-cause mortality or CV
hospitalization
PALLAS9 3236 Permanent Placebo 2.29-fold increase in primary composite
endpoint (first stroke, systemic arterial
embolism, myocardial infarction, or CV
death) (95% CI 1.34–3.94; P=0.002)
AF, atrial fibrillation; bid, twice daily; b.p.m., beats per minute; CHF, congestive heart failure; CI, confidence interval; CV, cardiovascular; HR, hazard ratio.
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New post-approval studies on the safety and efficacy of dronedar-
one have been completed, and the results of these studies and their
place in the context of past trials is the subject of this review.
Safety of dronedarone
During a review of the benefit–risk balance of dronedarone with
regards to liver safety, the results of the PALLAS trial were communi-
cated. In this comprehensive review, the EMA concluded that there
remained a positive benefit–risk balance for dronedarone treatment in
patients with paroxysmal or persistent AF. However, dronedarone
should neither be used in patients with permanent AF, nor in patients
with HF of New York Heart Association (NYHA) functional Class IV,
or NYHA Class II–III with recent decompensation requiring hospitali-
zation or in the presence of left ventricular dysfunction (ejection frac-
tion <_35%).15 Given the extensive clinical development programme,1–
3 dronedarone was given a Class IA recommendation in the European
Society of Cardiology (ESC) 2010, 2012, and 2016 guidelines, as well
as the American College of Cardiology (ACC)/American Heart
Association (AHA)/Heart Rhythm Society (HRS) 2014 guidelines for
prevention of symptomatic paroxysmal/persistent AF in patients with-
out HF, and a Class III recommendation for use in patients with HF or
permanent AF.16–19
In recent years, several real-world studies and a number of meta-
analyses have been conducted on dronedarone and other AADs,
which have further assessed the safety profile of dronedarone
(Table 2). Figure 1 shows a timeline of the key dronedarone studies
and milestones.
A report by the Cochrane Collaboration of 59 studies, 21 305
patients found that several AADs, including amiodarone, dronedar-
one, flecainide, and sotalol, were effective at preventing AF
recurrence, but were also discontinued due to adverse events (AE)
(Figure 2A). A significantly increased mortality rate was associated
with sotalol treatment (number needed to treat to harm: 169; 95%
CI 60–2068), but comparisons of mortality between other Class III
AADs and placebo found no significant differences (Figure 2B).25
Trends towards increased mortality for amiodarone have also been
found in a meta-analysis of RCTs studying amiodarone, dronedarone,
flecainide, propafenone, and sotalol vs. placebo [odds ratio (OR)
2.17, 95% CI 0.63–7.51].21 On the contrary, in trials of paroxysmal or
persistent AF, dronedarone has not shown any signals of increased
mortality associated with its use.1,3,4
In a recent real-world study analysing data of 300 000 patients with
AF from the Swedish patient registry, those prescribed dronedarone
or flecainide had a significantly lower all-cause mortality than sotalol
(HR 0.44, 95% CI 0.34–0.57 or HR 0.55, 95% CI 0.44–0.68, respec-
tively), while dronedarone was the only AAD associated with a lower
risk of ventricular proarrhythmia vs. sotalol (HR 0.58, 95% CI 0.37–
0.90).29 However, these results should be interpreted with caution as
an important limitation of the study is confounding by indication;
drugs have been selected non-randomly by information available to
the clinician. Although the author performed a frailty analysis, the full
severity of the patient’s condition cannot be accounted for in the
study.33
In the canine heart, dronedarone (and amiodarone) eliminates
early afterdepolarization activity induced by sotalol and other Class III
AADs known to cause QT-prolongation and torsades des pointes.34
Additionally, in RCTs, dronedarone has been shown to have low
proarrhythmic potential. In the ATHENA trial, the incidence of ven-
tricular arrhythmia was comparable with placebo,3 while there were
no reported episodes of torsades de pointes with dronedarone in
the dose-ranging study, DAFNE, nor in other pre-approval dronedar-
one trials (EURIDIS, ADONIS, ERATO, ANDROMEDA, and
DIONYSOS).2–4,7,8 In the 2015 Cochrane report, only three
AADs—amiodarone, dronedarone, and propafenone—did not
significantly increase proarrhythmia vs. controls (Figure 2C).25 In a
meta-analysis of RCTs investigating AADs vs. placebo, dronedarone
was associated with the lowest rate of proarrhythmia, including bra-
dycardia (OR 1.45, 95% CI 1.02–2.08).21
A recent retrospective analysis of the German IQVIA database
(2010–2017) involved 3498 patients receiving a first prescription of
dronedarone and 17 724 patients receiving a first prescription of
other AADs (amiodarone, flecainide, propafenone, or sotalol). The
authors found that dronedarone was associated with a decreased
risk of myocardial infarction (HR 0.78, 95% CI 0.63–0.96; P= 0.020)
and stroke (HR 0.84, 95% CI 0.71–0.99; P= 0.043) in patients with AF
compared with other AADs.31 These results are consistent with data
from the post hoc studies based on the ATHENA trial, which demon-
strated that patients with AF receiving dronedarone had reduced risk
of a first acute coronary syndrome and stroke vs. patients receiving
placebo.35,36 The most likely mechanism by which dronedarone
reduces the risk of stroke is by inhibition of AF and a slower ventricu-
lar rate.35 In addition, dronedarone has been shown to prevent mi-
crovascular flow alterations in the left ventricle during AF,37,38 and
also reduce the size of myocardial infarctions in porcine models.39
Interactions between anticoagulant
drugs and dronedarone
Interactions with direct oral anticoagulants
The risk of stroke is five-fold higher in patients with AF, and the risk
reduction from anticoagulant therapy is approximately 65%.40
Treatment with DOACs is associated with a lower risk of life-
threatening intracranial bleeding and AEs than the commonly used
vitamin K antagonist warfarin.41–44 Clinical data are limited and there
is a shortage of pharmacokinetic (PK)/pharmacodynamic (PD) data
on the use of DOACs with dronedarone. An important consider-
ation when evaluating interactions between DOACs and dronedar-
one is permeability glycoprotein (P-gp) inhibition. Permeability
glycoprotein plays a key role in the export of drugs from cells in the
small intestine, blood–brain barrier, kidney proximal tubule and
hepatocytes, and protects against foreign substances. A number of
drugs, such as dronedarone, are known P-gp inhibitors, and when
co-administered with DOACs can result in increased DOAC con-
centrations, consequently increasing the risk for bleeding.45 Known
interactions between DOACs and dronedarone are summarized in
Supplementary material online, Table S1.
Interactions
Apixaban
There is no specific advice regarding the concomitant use of drone-
darone with apixaban due to lack of PK/PD data.46 Recently, the clini-
cal safety of apixaban when combined with dronedarone was
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analysed in a Swedish registry study of patients with AF. Intracranial
bleeding, bleeding leading to hospitalization, and fatal bleeding events
were compared in two propensity-matched cohorts of 1681
dronedarone-treated patients with AF in combination with either
apixaban or warfarin (2013–2016).28 Treatment according to label
with apixaban 5 mg twice daily (bid) concomitantly with dronedarone
was not associated with more bleeding events than a combination of
warfarin and dronedarone (HR 0.66; P= 0.121) (Figure 3); however,
the study did not possess the statistical power to show non-
inferiority. Overall, major bleeding events in patients with AF treated
with dronedarone and either warfarin or apixaban were rare.28
These observational data suggest that dronedarone is safe to use in
combination with the standard dose of apixaban, but the study was
not powered to demonstrate a reduction in major bleeding or better
survival vs. warfarin, as in the randomized trial comparing the two
drugs.47,48
Dabigatran
Dabigatran is currently contraindicated with dronedarone by the EMA
based on a PK study of 16 healthy volunteers treated with 400 mg dro-
nedarone and 150 mg dabigatran, where the plasma concentration of
dabigatran was increased by 1.7-fold.49 In a recent real-world study, in
a cohort of 33 patients with AF treated with 400 mg dronedarone and
110 mg dabigatran, the median trough plasma concentration of dabiga-
tran was similar to that found with a dose of 150 mg dabigatran with-
out concomitant use of dronedarone, which was used in the RE-LY
trial.32,43 No formal PK/PD studies have been performed studying the
interaction between dronedarone and dabigatran 110 mg bid.
Edoxaban
For the more recently approved DOAC, edoxaban, the potential inter-
action with dronedarone is deemed to be moderate based on data from
the ENGAGE-AF study,41 and the summary of product characteristics
....................................................................................................................................................................................................................
Table 2 Meta-analyses and recent real-world studies conducted on dronedarone
Meta-analysis Studies analysed/registries used Main conclusion
Piccini et al.20 9 RCTs (4 dronedarone, 4 amiodarone, 1 RCT for
direct comparison analysis)
Dronedarone has fewer adverse effects than amiodarone but is
less effective at maintenance of SR
Freemantle et al.21 39 RCTs (amiodarone, dronedarone, flecainide,
propafenone, sotalol)
Dronedarone was associated with lowest rate of proarrhythmia
among AADs
Dagres et al.22 4 RCTs (dronedarone) Reduced risk of stroke or transient ischaemic attack with
dronedarone in paroxysmal or persistent AF
Chatterjee et al.23 7 RCTs (dronedarone) Increased all-cause mortality with use of dronedarone in a wide
spectrum of populations
Hohnloser et al.24 7 RCTs (dronedarone) Presence of permanent AF was most important predictor of CV
death with dronedarone
Lafuente-Lafuente et al.25 59 RCTs (quinidine, disopyramide, aprindine,
bidisomide, flecainide, propafenone, metoprolol,
amiodarone, azimilide, dofetilide, dronedarone,
sotalol)
Several class IA, IC, II and III drugs have a moderate effect on
maintaining SR following conversion of AF
Diemberger et al.26 12 RCTs and 7 OBS (dronedarone) Dronedarone use for prophylaxis of AF recurrences was not
associated with increased risk of death
Recent real-world studies Registries used
Friberg27 Swedish patient register Patients with AF prescribed dronedarone did not have an in-
creased risk of death or liver disease compared with patients
with AF not receiving dronedarone
Friberg28 Swedish patient register Major bleeding was rare in patients with AF treated with apixaban
in combination with dronedarone
Friberg29 Swedish patient register Dronedarone had a significantly lower risk for pro-arrhythmic
death than sotalol
Grimaldi-Bensouda et al.30 PGRx surveillance system Association in use of class III antiarrhythmic with onset of acute
liver injury
Ehrlich et al.31 German IQVIA database Dronedarone was associated with lower risk of myocardial infarc-
tion and stroke vs. other AADs. No cases of toxic liver disease
were reported in patients treated with dronedarone and other
AADs
Mochalina et al.32 Swedish national quality registry (AuriculA) A lower dose of dabigatran used concomitantly with dronedarone
did not increase the plasma concentration of dabigatran
AAD, antiarrhythmic drug; AF, atrial fibrillation; CV, cardiovascular; OBS, observational study; RCT, randomized controlled trial; SR, sinus rhythm.
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for edoxaban recommends using a half-dose [30 mg once a day (od)]
when used with dronedarone.50 Edoxaban is the only DOAC that has
been studied for use with dronedarone; an open-label, randomized,
two-period, two-treatment crossover study of 34 healthy volunteers
showed that co-administration of edoxaban with dronedarone in-
creased the edoxaban 24 h plasma concentration by 158%, while amio-
darone decreased the 24 h plasma concentration of edoxaban by 26%.
As a previous pharmacometric analysis predicted that increased edoxa-
ban exposure associated with dronedarone would result in significant
bleeding,51 the results of this study suggested that prescribing edoxaban
without dose reduction presents a potential risk of bleeding in patients
receiving dronedarone.52
Rivaroxaban
There is no specific advice for the concomitant use of dronedarone
with rivaroxaban due to shortage of PK/PD data.46 However, in a
recent study of 23 patients with paroxysmal AF for 9.1± 6.7 months,
concomitant use of dronedarone and rivaroxaban was not associated
with significant AEs.53
Other data on direct oral anticoagulants and dronedarone
In a retrospective cohort study on a Taiwanese population of 91 330
patients with non-valvular AF, no difference was found in the adjusted
incidence rate ratio of major bleeding risk between concomitant use
of dronedarone and dabigatran (0.89, 99% CI 0.54–1.45), apixaban
(0.68, 99% CI 0.33–1.41), or rivaroxaban (0.92, 99% CI 0.68–1.24) vs.
DOAC use alone. In contrast, amiodarone increased the risk of ma-
jor bleeding when used concomitantly with dabigatran or rivaroxaban
vs. DOAC use alone.54
Randomized controlled trials investigating concomitant use of dro-
nedarone with DOACs are limited. This is particularly true for dabi-
gatran and rivaroxaban, which have only been studied in combination
ANDROMEDA 2003
Effects in severe HF
PALLAS 2011
Effects in permanent AF
DIONYSOS 2009
Dronedarone vs
amiodarone in AF
ATHENA 2008
Outcomes in AF
Approval by
EMA/FDA
2014
AHA/ACC/HRS
AF guidelines
German IQVIA
database
PGRx surveillance
systemCautions by
EMA/FDA
Potential
liver toxicity
Phase IV studies
EU pivotal Phase III studies
US/EU pivotal Phase III studies RWE studies
Other milestone events
ODYSSEUS 2012
AF remodelling
HARMONY 2014
Ranolazine and
dronedarone in
paroxysmal AF
HESTIA 2012
AF pacemaker
Swedish drug
prescription registry
2014–2018
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(AuriculA)
ERATO 2003
Effects on ventricular
rate in permanent AF
EURIDIS/ADONIS 2003
Antiarrhythmic effects
DAFNE 2000
Dose-ranging
2000–2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Figure 1 Timeline of key milestones for dronedarone. ACC, American College of Cardiology; AF, atrial fibrillation; AHA, American Heart Association;
EMA, European Medicines Agency; FDA, Food and Drug Administration; HF, heart failure; HRS, heart rhythm society; RWE, real-world evidence.
Drugs studied
A B C
Class IA disopyramide 3.85 (1.13–13.2)
Withdrawals Overall Mortality Proarrhythmia
Peto Odds Ratio (95% Cl) Peto Odds Ratio (95% Cl) Peto Odds Ratio (95% Cl)
9.14 (1.94–42.9)
1.69 (1.09–2.62)
1.64 (1.38–1.94)
1.68 (0.79–3.59)
5.55 (2.24–13.7)
1.78 (1.57–2.01)
a1.90 (0.90–4.02)
a2.33 (1.34–4.04)
no event
a1.99 (0.76–5.25)
3.26 (2.13–4.98)
3.79 (1.54–9.33)
2.65 (0.88–8.00)
2.10 (1.02–4.33)
5.25 (1.76–15.6)
1.52 (0.33–7.02)
3.21 (2.62–3.93)
no event
no event
0.98 (0.68–1.41)
1.64 (0.59–4.56)
2.26 (0.93–5.45)
7.56 (0.47–122)
2.23 (1.10–4.50)
1.03 (0.85–1.24)
0.85 (0.67–1.09)
0.1 1 10 0.10 1 10 0.1 1 10
quinidine
flecainide
propafenone
amiodarone
dofetilide
dronedarone
sotalol
all class III
Class IC
Class III
Figure 2 Withdrawals (A), overall mortality (B), and proarrhythmia (C) reported in clinical trials for antiarrhythmic drugs. Reproduced with permis-
sion and modified from Lafuente-Lafuente et al.25 aOdds ratio calculated by random effects model, as test for heterogeneity between pooled studies
was significant. Some studies compared more than two drugs, so the total number of studies and patients in the figure is higher than the absolute num-
ber of studies and patients included. CI, confidence interval.
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with dronedarone in a recent small study.53 Despite the lack of PK/
PD studies, recent real-world data on combined therapy with the
standard dose of apixaban suggested concomitant use of dronedar-
one and apixaban was not associated with significant safety risks
when compared with dronedarone in combination with warfarin.28
Interactions with vitamin K antagonists
The enzymes CYP2C9, CYP3A4, and CYP1A2 are the main routes of
metabolism for warfarin; their inhibition increases the international nor-
malized ratio (INR) and the risk of bleeding, requiring a lower dose of
warfarin when amiodarone is administered.55 Dronedarone does not
significantly inhibit CYP2C9 but is a moderate inhibitor of CYP3A4,
while amiodarone, in comparison, interferes substantially with warfarin
treatment by inhibiting CYP2C9, CYP3A4, and CYP1A2. In the
DIONYSOS study, a smaller proportion of patients receiving drone-
darone had supratherapeutic INR levels vs. patients receiving amiodar-
one, suggesting that dronedarone had fewer interactions with oral
anticoagulants than amiodarone.15 For other CYP2C9 and CYP1A2
substrates, no interactions have been observed with dronedarone.
In 2009, the dronedarone briefing document submitted to the Food
and Drug Administration (FDA) reported no safety concerns regard-
ing drug–drug interactions of dronedarone with warfarin, as no clini-
cally significant PK interaction was observed between the two drugs.56
International normalized ratio elevations have been reported in post-
marketing cases in warfarin-treated patients initiated on dronedarone,
and the EMA recommends monitoring INR levels following initiation
with dronedarone when treated concomitantly with warfarin.57
Concomitant use of digoxin with
dronedarone
Digoxin treatment itself may be associated with an increase in all-
cause mortality in patients with AF, as found in a retrospective analy-
sis of the ROCKET-AF trial,42 and when used for rate control in
patients with AF with or without HF in the AFFIRM study.58 Similarly,
in a systematic review and meta-analysis of the literature (1993–
2014) on digoxin-associated mortality, digoxin was associated with a
29% increased mortality risk in the subgroup of 235 047 patients with
AF compared with those patients not receiving digoxin (HR 1.29,
95% CI 1.21–1.39; P< 0.01).59 An updated systematic review and
random-effect meta-analysis on publications up to March 2018 con-
firmed these results. New digoxin users (n= 41 687) showed an even
higher risk for all-cause mortality vs. patients not receiving cardiac gly-
cosides (HR 1.47; 95% CI 1.15–1.88; P< 0.01).60 These data suggest
that digoxin use is associated with an increased mortality risk, espe-
cially for patients with AF.
Although several studies suggested dronedarone had a better
safety profile than amiodarone—presenting a low risk of proarrhyth-
mia, in both the ANDROMEDA and PALLAS trials—negative effects
of dronedarone were seen in patients with severe chronic HF and de-
pressed left ventricular systolic function.8 Increased mortality was
seen in the PALLAS trial [21 deaths from CV causes in the dronedar-
one group and 10 deaths in the placebo group (HR 2.11; 95% CI
1.00–4.49; P= 0.046), including 13 deaths from arrhythmia in the dro-
nedarone group and 4 deaths in the placebo group (HR 3.26, 95% CI
1.06–10.00; P= 0.03)], but a significant number of these patients
were treated with digoxin concomitantly with dronedarone.9,61
A PK interaction is known to exist between dronedarone and
digoxin. As a P-gp inhibitor, dronedarone reduces the renal excretion
of digoxin, increasing its serum concentration to toxic levels.45
Also, a study on experimental models comparing concomitant use of
dronedarone and amiodarone with the digitalis glycoside ouabain in
rabbits found that ouabain mediated a shortening of the ventricular
refractory period, opposing the antiarrhythmic increases induced by
dronedarone or amiodarone.62 Ouabain treatment together with
dronedarone resulted in greater ventricular vulnerability to malignant
ventricular arrhythmias compared with rabbits treated with a combi-
nation of ouabain and amiodarone, which also demonstrated an
Endpoint
Hazard ratio Events
apixaban warfarin
Events
(95% Cl)
MAIN ENDPOINT
Intracranial
Any bleeding hospitalisation
Fatal bleeding
GI bleed hospitalisation
Death from any cause
Falsification endpoint
Favours Apixaban
0.1 0.5 1.0 1.5 2.0 3.0 5.0
Favours Warfarin
Open care bleed
Other bleed hospitalisation
Urogenital bleed hospitalisation
SECONDARY ENDPOINTS
1.04 (0.69, 1.57)
1.45 (0.42, 5.03)
0.84 (0.59, 1.19)
0.71 (0.16, 3.06)
0.92 (0.06, 14.70)
0.62 (0.33, 1.17)
0.23 (0.03, 2.05)
0.66 (0.35, 1.23)
3
3
6
1 1
16 26
17 26
1 4
5
10 18
62 71
7 4
48 48
0.64 (0.15, 2.79)
0.55 (0.25, 1.21)
Figure 3 Hazard ratios for bleeding outcomes with apixaban–dronedarone and warfarin–dronedarone combinations. Reproduced with permission
from Friberg.28 CI, confidence interval; GI, gastrointestinal.
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increased risk of proarrhythmia.62 In line with these findings, a case
report showed that the combination of amiodarone and digitalis
resulted in torsades de pointes in a patient with tachycardiomyopathy
and no coronary artery disease.63
Hence, PK/PD data and experimental animal data support that in
combination with dronedarone, digitalis may be harmful and should
be avoided. In line with the above data, in a retrospective analysis of
the PALLAS trial, concomitant digoxin use had a significant effect on
the hazard of dronedarone on all-cause mortality and arrhythmic
death in patients with permanent AF (Table 3). The study suggests
that the interaction between dronedarone and digoxin was responsi-
ble, in part, for most of the increased arrhythmic mortality observed
in the PALLAS trial.61
Although the PALLAS trial demonstrated an increased risk of
mortality, based on real-world data, there are no signs of increased
mortality associated with dronedarone treatment vs. control.
Specifically, an analysis of the Swedish Drug Prescription Register
found that mortality rates (unadjusted) were lower for dronedarone-
treated patients with AF (1.3%, 95% CI 1.1–1.6) than control patients
(14.0%, 95% CI 13.9–14.2; P< 0.0001), including patients with a
history of HF. Following propensity score matching and adjustment
for cofactors (previous and current diseases and medication),
dronedarone-treated patients still demonstrated lower mortality
than other patients with AF (HR 0.41, 95% CI 0.33–0.51).27
However, as mentioned previously, these real-world data should be
interpreted with caution.33
To conclude, there are divergences in the safety profile of drone-
darone between RCTs and real-world observational studies, and
concomitant use of digoxin in RCTs may play a significant part in this
disparity.
Data on liver safety
Although no concerns were raised about liver toxicity associated
with dronedarone use in RCTs, in 2011, two reported cases of se-
vere liver injury requiring organ transplantation prompted the EMA
to perform a comprehensive review of all available data on potential
liver toxicity caused by dronedarone. As a result, new warnings and
precautions were introduced in the summary of product characteris-
tics for dronedarone, and frequent LFTs were recommended.15
Currently, the strategies employed by the FDA and EMA to monitor
potential liver toxicity associated with dronedarone use differ sub-
stantially (Figure 4), and compared with the FDA, the EMA’s regula-
tions are more restrictive regarding LFTs for dronedarone-treated
patients.64
Recent experimental data suggest that amiodarone- and
dronedarone-induced hepatotoxicity may occur through a similar
mechanism, specifically the inhibition of mitochondrial fatty acid b-
oxidation,65 and that, due to the lower lipophilicity of dronedarone
compared with amiodarone, only specific patients may reach a high
enough hepatic concentration of dronedarone to lead to hepatocyte
damage.66
In a previously unpublished analysis of liver safety, based on data
from five RCTs studying dronedarone in patients with paroxysmal or
persistent AF (DAFNE, EURIDIS, ADONIS, ERATO, and ATHENA),
no statistically significant difference was found in hepatobiliary disor-
ders reported between dronedarone and placebo. A greater percent-
age of patients experienced hepatic events with dronedarone
treatment than placebo when time to first hepatic event or an alanine
aminotransferase (ALT) >_5 upper limit of normal (ULN) were ana-
lysed (dronedarone 400 mg bid: 3.4%, N= 3531; placebo: 2.6%,
N= 2875). However, no significant difference was found in the num-
ber of hepatic events between dronedarone and placebo when time
to first serious hepatic event was examined (dronedarone 400 mg bid:
n= 97, N= 3282; placebo: n= 74, N= 2875; P= 0.2566) (Table 4).
Focusing on post-marketing data, the Pharmacoepidemiologic
General Research Extension study on acute liver injury cases (de novo
elevation of liver enzymes) found an association between the use of
Class III antiarrhythmics and onset of acute liver injury, mainly driven
by amiodarone, demonstrating a greater risk (adjusted OR 5.90, 95%
CI 1.7–20.0; P= 0.0044) than dronedarone (adjusted OR 3.13, 95% CI
0.7–14.8; P= 0.1505). The risk associated with Class I AADs was not
statistically significant (adjusted OR 2.08, 95% CI 0.52–8.29;
P= 0.2970).30 The recent, prospective, comparative cohort EFFECT-
AF trial found that the rate of liver injury/toxicity among
....................................................... ....................................................... ...................................................
....................................................................................................................................................................................................................
Table 3 All-cause mortality and arrhythmic deaths according to baseline digoxin use in a subgroup analysis of the
PALLAS trial61
Placebo Dronedarone Dronedarone vs. placebo
Outcome Events/N Number of events/
100 patient-monthsa
Events/N Number of events/
100 patient-monthsa
HR 95% CI P value
All-cause mortality (interaction P = 0.02)
Overall 13/1617 0.2 25/1619 0.39 1.94 0.99–3.79 0.05
No digoxin 10/1091 0.23 8/1075 0.19 0.82 0.32–2.08 0.67
Digoxin at baseline 3/526 0.15 17/544 0.81 5.47 1.60–18.66 0.007
Arrhythmic death (interaction P = 0.002)
Overall 4/1617 0.06 13/1619 0.21 3.26 1.06–10.00 0.04
No digoxin 4/1091 0.09 2/1075 0.05 0.51 0.09–2.76 0.43
Digoxin at baseline 0/526 0.0 11/544 0.53 22.70b 1.33–386.17b 0.03
aTotal number of events/total patient-months  100.
bRisk was estimated as an odds ratio from a logistic regression with 0.5 added to each group.
CI, confidence interval; HR, hazard ratio.
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Amiodarone
Initiation
Dronedarone
Week 1 Months 1–5 Month 6 Month 9 Month 12 Beyond 12 months
LFT
LFT LFT LFT LFT LFT LFT
LFTLFT
Every 6
months
Yearly
Figure 4 Differences in LFT regulations of EMA for amiodarone and dronedarone. EMA, European Medicines Agency; LFT, liver function test.
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Table 4 Liver safety data from clinical trials with dronedarone
Number of patients with at least one post-baseline PCSA in liver parameters up to the last study drug intake110 days during the
on-treatment perioda
Placebo Dronedarone Amiodarone
Parameter PCSA criteria N5564 400 mg bid 600 mg bid 800 mg bid 600 mg/200 mg od
N5 1238 N566 N5 62 N5 255
ALT (SGPT-ALAT) >2  ULN 34/ 559 (6.1%) 86/1227 (7.0%) 16/66 (24.2%) 6/56 (10.7%) 34/254 (13.4%)
>3  ULN 11/559 (2.0%) 35/1227 (2.9%) 3/66 (4.5%) 2/56 (3.6%) 10/254 (3.9%)
>5  ULN 5/559 (0.9%) 10/1227 (0.8%) 1/66 (1.5%) 0/56 (0.0%) 2/254 (0.8%)
AST (SGOT-ASAT) >2  ULN 16/558 (2.9%) 40/1227 (3.3%) 1/66 (1.5%) 1/56 (1.8%) 14/254 (5.5%)
>3  ULN 6/558 (1.1%) 14/1227 (1.1%) 1/66 (1.5%) 0/56 (0.0%) 3/254 (1.2%)
>5  ULN 0/558 (0.0%) 8/1227 (0.7%) 0/66 (0.0%) 0/56 (0.0%) 2/254 (0.8%)
Overview of patients with hepatic event (AE or ALT 5 x ULN)b
Placebo Dronedarone Amiodarone
N52875 400 mg bid 600 mg bid 800 mg bid 600 mg/200 mg od
N5 3531 N566 N5 62 N5 255
TEAEs 74 (2.6%) 119 (3.4%) 4 (6.1%) 2 (3.2%) 14 (5.5%)
Serious TEAEs 33 (1.1%) 39 (1.1%) 1 (1.5%) 0 (0.0%) 3 (1.2%)
AEs leading to premature study drug discontinuation 7 (0.2%) 17 (0.5%) 0 (0.0%) 0 (0.0%) 6 (2.4%)
Serious TEAEs leading to hospitalization 26 (0.9%) 28 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%)
Serious TEAEs leading to death 2 (<0.1%) 1 (<0.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Unadjusted analysis of time from randomization to first hepatic event or ALT 53ULN during the on-treatment periodc
Placebo Dronedarone 400 mg bid
N5 2875 N5 3282
Number of events, n 74 97
Median survival (95% CI) (months)d NC (NC to NC) NC (NC to NC)
Cumulative incidence of events (95% CI)d
6 months 0.013 (0.009–0.018) 0.020 (0.015–0.026)
1 year 0.022 (0.016–0.028) 0.030 (0.023–0.036)
2 years 0.040 (0.030–0.050) 0.039 (0.031–0.047)
Log-rank test P-valuee – 0.2566
Relative risk (95% CI)f – 1.018 (0.749–1.385)
aAll randomized and treated patients with AF/AFL excluding patients from the ATHENA trial.
bAll randomized and treated patients in AF/AFL studies (DAFNE, EURIDIS, ADONIS, ATHENA, ERATO, and DIONYSOS).
cAll randomized and treated patients with AF/AFL excluding patients from the DIONYSOS trial.
dKaplan–Meier estimates.
eLog-rank test.
fHazard ratio adjusted on studies using Cox model.
AE, adverse event; AF, atrial fibrillation; AFL, atrial flutter; ALT, alanine transaminase; AST, aspartate transaminase; bid, twice a day; CI, confidence interval; NC, not calculated;
od, once daily; PCSA, potentially clinically significant abnormalities; SGOT-ASAT, serum glutamic oxaloacetic transaminase-aspartate aminotransferase; SGPT-ALAT, serum glu-
tamic-pyruvic transaminase-alanine aminotransferase; TEAE, treatment-emergent adverse event; ULN, upper limit of normal.
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dronedarone-treated patients was only numerically higher than
patients treated with other AADs (1.33/100 person-years vs. 0.38/100
person-years; P= 0.0936), and most of the cases of liver injury/toxicity
in dronedarone-treated patients were non-serious reports of liver en-
zyme increases. There were two hospitalizations for liver toxicity
events (one in the dronedarone group and one in the other AADs
group) and both were classified as moderate. Based on the different
regulatory requirements regarding LFTs for dronedarone and other
AADs (Figure 4), it is likely that a greater number of LFTs were con-
ducted on dronedarone-treated patients during the study period vs.
amiodarone.67 Data from a post hoc analysis from the DIONYSOS trial
demonstrate a similar frequency of ALT/aspartate transaminase eleva-
tions in LFTs between dronedarone- and amiodarone-treated patients
(Figure 5). These findings suggest that there might not be a need for
more stringent, systematic liver enzyme measurements via LFTs in
patients who receive dronedarone vs. those who receive amiodarone.
Real-world studies published since 2012 indicate there are no
safety issues regarding serious liver damage with dronedarone. In the
recent retrospective analysis of the German IQVIA database (2010–
2017), which included patients initiated on dronedarone or other
AADs (amiodarone, flecainide, propafenone, or sotalol), there were
no reported cases of toxic liver disease in either group. In dronedar-
one patients, gamma-glutamyl transferase changed from 45.5 to
41.6 IU/L, while in patients treated with other AADs it changed from
52.2 to 48.1 IU/L. There was no significant difference between the
two groups when comparing the value changes prior to and after the
index date (P= 0.185).31 A retrospective cohort study of an elec-
tronic medical record and an administrative claims data source
(2009–14) found no evidence of increased risk of serious liver disease
or interstitial lung disease in patients with AF treated with dronedar-
one vs. other AADs.68 In the analysis of the Swedish patient register
(300 000 patients with AF), the incidence of new liver disease was low
in all drug cohorts (dronedarone: 0.18/100 person-years at risk;
amiodarone: 0.32/100 person-years at risk), and similar to that of
patients with AF not treated with AADs (0.29/100 person-years at
risk).29
Importantly, there is evidence suggesting that elevations in liver
enzymes may occur regularly in patients with AF in routine clinical
care—a probable result of their comorbidities and concomitant medica-
tion. In a retrospective study of 2151 patients with AF, the incidence of
elevations of new ALT 2  ULN was 2.1/100 person-years, and nearly
all of the new elevated ALT measurements in the study were transient.69
Similarly, in the RE-LY trial, ALT levels >3  ULN were found in 2.1%
and 2.2% of patients treated with dabigatran or warfarin, respectively,43
suggesting that transient elevated ALT is common among patients with
AF. Consequently, it may be difficult to correctly identify drug-induced
increases in LFTs, particularly in the setting of new drug trials.69
Consequently, the data suggest that the rate of liver events associ-
ated with dronedarone use is comparable or lower than that ob-
served for other AADs, and the EMA recommendations for LFTs do
not reflect the whole body of evidence (clinical trials and real-world
studies) presented here. There are also relevant differences between
the FDA and EMA recommendations for LFTs (Table 5), where the
recommended multiple LFTs during initiation of treatment with dro-
nedarone in Europe may be perceived as overcautious.
Efficacy
Hospitalization
In a retrospective, real-world practice cohort study in 5656 patients
with AF or atrial flutter, CV-related and AF-related hospitalization
rates decreased by 41–45% (P< 0.0001) with dronedarone treat-
ment vs. baseline, and all-cause hospitalization was significantly re-
duced by 39%.70 In addition, in a retrospective study using the US
Department of Defense electronic health record database between
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Figure 5 The Kaplan–Meier cumulative incidence curves from first study drug intake to first increase in liver enzymes (ALT and/or AST >_2 ULN
and increase of >0.5ULN from baseline value) in DIONYSOS. ALT, alanine transaminase; AST, aspartate transaminase; ULN, upper limit of normal.
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2009 and 2011, dronedarone-treated patients with AF demonstrated
significantly lower rates of CV hospitalizations and/or death from any
cause compared with patients treated with other AADs (HR 1.24,
95% CI 1.05–1.47; P= 0.011). Similar results were demonstrated for
most CV outcomes, apart from non-hospitalized cardioversion,
which was significantly lower with other AADs than with dronedar-
one (HR 0.81, 95% CI 0.71–0.92; P= 0.001).71 These results are con-
sistent with the ATHENA trial,1 demonstrating the effect of
dronedarone on CV hospitalizations and mortality vs. placebo, along
with lower mortality rates vs. other AADs.
Atrial fibrillation burden
The efficacy of dronedarone was also explored in relation to AF bur-
den in the HESTIA trial. Relative AF burden, assessed through dual-
chamber pacemakers, was reduced by 59% in patients who received
dronedarone vs. placebo (absolute reduction in AF burden of 5.5% in
the dronedarone group and increase of 1.1% in the placebo group).5
In addition, in a retrospective analysis of the EURIDIS and ADONIS
trials, dronedarone decreased the risk of AF recurrences by 30.4%
vs. placebo in patients without permanent AF and who were previ-
ously treated with any AAD (HR 0.70, 95% CI 0.59–0.82; P< 0.001),
even if the reason for discontinuation was lack of efficacy.72
Comparative studies with other
antiarrhythmic drugs
There are limited head-to-head comparisons of dronedarone and
other AADs. Although dronedarone was less effective at decreasing
AF recurrence in the DIONYSOS trial, dronedarone demonstrated a
better safety profile and lower premature drug discontinuation vs.
amiodarone (10.4% vs. 13.3%).4 The safety benefits with dronedar-
one vs. amiodarone were demonstrated despite the short follow-up
of this study, which may have limited the number of AEs often seen
with long-term use of amiodarone.4 A meta-analysis on the safety of
amiodarone and dronedarone in RCTs found that dronedarone ther-
apy was associated with fewer AEs and less discontinuation of
treatment than amiodarone therapy, although the efficacy of drone-
darone in maintaining SR was lower than amiodarone.20
In the EFFECT-AF study (actual drug use analysis), dronedarone
had a similar effectiveness profile to the group of other AADs (Class
IA/IC AADs, sotalol, and amiodarone) in confirmed AF recurrence
rates (49.93/100 person-years and 53.83/100 person-years, respec-
tively; P= 0.4269). However, there were significantly lower rates of
CV hospitalizations and HF in dronedarone- vs. other AAD-treated
patients (24.72/100 person-years vs. 39.78/100 patient-years;
P= 0.0001).67
In a retrospective cohort study including 123 consecutive patients
with paroxysmal or persistent AF treated with either dronedarone
or flecainide, dronedarone treatment was as effective as flecainide in
reducing AF recurrence, with an acceptable safety profile in compari-
son with flecainide (HR 0.68, 95% CI 0.18–2.53; P= 0.566). There
were AF recurrences in 36.6% of flecainide-treated patients vs. 21%
in the dronedarone arm (P= 0.073), despite more frequent prescrip-
tion of dronedarone in patients with more baseline comorbidities,
and after the failure of at least one previous AAD.73 A RCT compar-
ing the effect of dronedarone and propafenone (N= 98) in maintain-
ing SR in patients with AF following electrical cardioversion found
that the two drugs demonstrated similar efficacy. The median [range]
ventricular rate at first recurrence of AF was numerically lower for
dronedarone (76.5 [67.3–86.5] b.p.m.) vs. propafenone (83.0 [71.0–
96.0] b.p.m.); however, the difference was not statistically significant
(P= 0.059).74
In summary, dronedarone has been shown to be effective in reduc-
ing AF burden and CV hospitalization rates in both placebo-controlled
trials and real-world studies. When considered alongside its unique
safety profile, with a lower risk of ventricular pro-arrhythmia com-
pared with other AADs, these observations should be the principal
reasons for choosing dronedarone for rhythm control. This could be
particularly relevant in moderate-risk patients, such as those with hy-
pertensive cardiomyopathy or ischaemic heart disease.
Conclusion
Recent real-world studies coupled with post-market surveillance
have provided evidence that dronedarone is a safe and effective drug
for AF treatment. Several real-world studies have shown that the
liver safety profile of dronedarone is similar to that of other AADs,
while the risk of proarrhythmic events is lower with dronedarone
than with other agents. Data on the interaction between dronedar-
one and apixaban, and data on dronedarone and edoxaban in RCTs,
suggest there are no significant safety risks for patients receiving these
drugs, but there is less evidence to support the use of dronedarone
with other DOACs. The concomitant use of digoxin with dronedar-
one may have been responsible for some of the negative effects of
dronedarone in ANDROMEDA and PALLAS and should be avoided.
In addition, liver enzyme elevations seen in the AF population may be
a result of comorbidities and polypharmacy rather than one specific
drug. Although LFTs are recommended for dronedarone, as well as
for other agents with reported alterations of hepatic enzymes (e.g.
amiodarone), the more stringent EMA recommendations for drone-
darone do not take into account recent real-world studies presented
in this review.
........................................................................
.................................................................................................
Table 5 The differing approaches between agencies on
LFT policy for dronedarone
Organization Liver function testing policy for dronedarone
LFT before
treatment
LFTafter start of
treatment
FDA No Consider obtaining periodic hepatic
serum enzymes, especially during
the first 6 months of treatment
EMA Yes • After 1 week
• After 1 month of treatment
initiation
• Repeated monthly for first
6 months
• At months 9 and 12
• Periodically after first year
EMA, European Medicines Agency; FDA, Food and Drug Administration; LFT,
liver function test.
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Supplementary material is available at Europace online.
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